Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13119598 | 1.00 | FKBP1A (0.46) | FKBP1ATAAR1NPSR1TLR2TLR1 | |
| SCHEMBL3567863 | 0.78 | KMT2A (0.48) | FKBP1ACFDCYP2C19POLBMEN1 | |
| SCHEMBL3576076 | 0.78 | KMT2A (0.48) | FKBP1ACFDCYP2C19POLBMEN1 | |
| SCHEMBL8104234 | 0.78 | POLB (0.65) | FKBP1ACYP2C19POLBMEN1KMT2A | |
| SCHEMBL13141515 | 0.77 | F2 (0.45) | FKBP1ATAAR1NPSR1CFDCYP2C19 | |
| SCHEMBL8087843 | 0.77 | TAAR1 (0.44) | FKBP1ATAAR1NPSR1CFDCYP2C19 | |
| SCHEMBL16300666 | 0.77 | POLB (0.53) | NPSR1CYP2C19POLBMEN1KMT2A | |
| SCHEMBL8102664 | 0.77 | FKBP1A (0.64) | FKBP1ATAAR1NPSR1POLBGAA | |
| SCHEMBL13837974 | 0.76 | TDP1 (0.61) | TAAR1MEN1KMT2A | |
| SCHEMBL18546450 | 0.75 | POLB (0.48) | FKBP1ATAAR1NPSR1CFDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| WO-2009000878-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | KLK7, KLK5, KLKB1 | FKBP1A 2112/4885TAAR1 4157/4885NPSR1 1011/4885 |
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | FKBP1A 2112/4885TAAR1 4157/4885NPSR1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.